Topical Finasteride Systemic Absorption: Pharmacokinetic Data

The primary pharmacokinetic argument for topical over oral finasteride is that topical application limits how much drug enters systemic circulation, reducing systemic DHT suppression and potentially reducing systemic side effects. Here is what the published data show.

Key Pharmacokinetic Data

Study	Formulation	Serum DHT Reduction	Oral 1 mg Comparison
Caserini et al. 2016	Topical 0.25% solution	24% to 26% at 100 to 200 µL daily	No oral arm at these doses
Piraccini et al. 2022	Topical 0.25% spray	34.5%	Oral 1 mg: 55.6% (same trial)
Scalp DHT reduction (Caserini)	Topical 0.25%	About 70% at 1 mL once daily; 47% to 52% at 100 to 200 µL	Oral 1 mg: about 50%

What Does This Mean Clinically?

• Topical finasteride 0.25% produces a smaller serum DHT reduction than oral 1 mg (34.5% vs. 55.6% in Piraccini 2022), with peak plasma finasteride levels more than 100 times lower
• In Caserini 2016, 1 mL once daily cut scalp DHT by about 70% vs. about 50% with the 1 mg tablet, which points to meaningful local activity
• Whether these scalp DHT effects translate to meaningfully different hair regrowth vs. oral is not yet established in long-term head-to-head trials
• Formulation matters significantly, LADD (Liquid Atypical Drug Delivery) technology and different vehicles produce different skin permeation rates; data from one formulation should not be extrapolated to compounded preparations

See: Topical finasteride hub | Topical vs. oral comparison | Topical side effects | Clinical trials

Sources

• Caserini M, et al. “Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia.” Int J Clin Pharmacol Ther. 2016;54(1):19-27.
• Piraccini BM, et al. “Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia.” J Eur Acad Dermatol Venereol. 2022;36(2):286-294.